Trade Summary

1 week ago, Genmab A/S, serving as 10% owner at Merus N.V. (MRUS), purchased 815,444 shares at $97.00 per share, for a total transaction value of $79,098,068.00. Following this transaction, Genmab A/S now holds 72,828,509 shares of MRUS.

This purchase represents a 1.00% increase in Genmab A/S's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, December 22, 2025 and publicly disclosed via SEC Form 4 filing on Monday, December 29, 2025, 7 days after the trade was made.

Merus N.V. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.